Large-scale партнер Leverage argenx’s substantial funding and revenue scale to position joint development and co-investment opportunities with peers and academic partners, highlighting capability to support advanced immunology programs and rapid clinical expansion.

M&A accelerators Capitalize on the ongoing Forte Biosciences acquisition to explore complementary assets, licensing discussions, and rapid pipeline enhancement through strategic partnerships that align with argenx’s focus on autoimmune indications.

VYVGART momentum Target opportunities around VYVGART as a commercial success case to propose expansion collaborations, label expansions, and prescriber education programs with payers and specialty pharmacies to broaden market access.

Indication expansion Proactively map potential autoimmune indications such as vitiligo and celiac disease associated with FB102 and related pipelines to generate early BD conversations for co-development, phase II/III partnerships, or option rights.

Global reach Position argenx as a global immunology leader with a robust technology stack and partnerships (IIP network, Azure ML usage) to offer data-driven, multi-country clinical and market access initiatives appealing to large pharma collaborators seeking scalable solutions.